Corvus Pharmaceuticals, Inc. 8-K

What Happened
Corvus Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026 (record date April 16, 2026). Stockholders elected the company’s Class I director nominees Richard A. Miller, M.D., and Linda S. Grais, M.D., J.D., ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for fiscal 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. As of the record date there were 84,090,424 shares outstanding and 73,021,854 shares were voted in person or by proxy.

Key Details

• Record date and shares: 84,090,424 shares outstanding as of April 16, 2026.
• Votes cast at meeting: 73,021,854 shares voted in person or by proxy on June 11, 2026.
• Director elections:
  • Richard A. Miller, M.D.: For 58,275,179; Withheld 2,697,052; Broker non-votes 12,049,623.
  • Linda S. Grais, M.D., J.D.: For 53,185,380; Withheld 7,786,851; Broker non-votes 12,049,623.
• Auditor ratification: PwC ratified — For 72,864,335; Against 105,674; Abstain 51,845.
• Advisory vote on executive compensation: Approved — For 58,936,532; Against 1,971,370; Abstain 64,329; Broker non-votes 12,049,623.

Why It Matters
These outcomes confirm the board’s makeup and that shareholders supported the company’s auditor and executive pay policy (non-binding). The sizable number of broker non-votes (12,049,623) indicates a portion of shares voted by brokers under discretionary rules did not affect director and advisory tallies, which can be relevant when assessing shareholder engagement and governance dynamics.